Frontiers reaches 6.4 on Journal Impact Factors
Cardiovascular Biologics and Regenerative Medicine welcomes articles related to all aspects of cardiac regeneration including, but not limited to, biomaterials, cell therapy, gene therapy, genomics, proteomics and hybrid therapy.Read More
Frontiers in Cardiovascular Medicine is a global, peer-reviewed Open Access medical journal providing unrestricted, online access to publications on diagnostic and therapeutic advances in cardiology and cardiovascular disease. Frontiers in Cardiovascular Medicine publishes peer-reviewed scientific investigations of the highest quality that are of relevance for the diagnosis, treatment, or pathogenesis of cardiovascular disease and related disorders with the goal to understand disease processes and to improve medical practice and patient care.
For almost two centuries, the dream of repairing damaged human hearts has tantalized physicians, scientists and patients, alike. While amphibians and fish readily regrow internal organs and even limbs, the adult heart is capable of only very modest regenerative responses after injury. This frustrating limitation has left many patients with irreversible heart damage after a cardiac injury- limiting both quality of life and survival. But over the last two decades, research has emerged that native heart can be enticed to undergo cardiac repair and replace injured myocardium. The field of Cardiovascular Biologics and Regenerative Medicine has since emerged to harness these fundamental biological principles to impact upon clinical medicine.
Our mission at Cardiovascular Biologics and Regenerative Medicine is to be at the forefront of this field by rapidly disseminating experimental evidence, concepts and hypotheses to the broadest possible audience. We welcome articles related to all aspects of cardiac regeneration including, but not limited to, biomaterials, cell therapy, gene therapy, genomics, proteomics and hybrid therapy.
The Editors of Frontiers in Cardiovascular Medicine encourage submission of Original Research Articles (clinical or preclinical), Reviews, Mini Reviews and Case Reports. Original research articles include manuscripts reporting results from clinical investigations, including Phase I-III trials and population studies. Reports from experimental studies from related areas such as physiology, pathophysiology, cellular and molecular biology, genetics, or pharmacology may be considered as as long as they relate to new understandings of pathogenic mechanisms or novel therapeutic approaches relevant to human disease. Articles related to medical education or the future development of medicine may also be considered.
Indexed in: PubMed, PubMed Central, Google Scholar, DOAJ, CrossRef, Semantic Scholar, Ulrich's Periodicals Directory, ESCI, CLOCKSS
PMCID: all published articles receive a PMCID
Cardiovascular Biologics and Regenerative Medicine welcomes submissions of the following article types: Case Report, Clinical Study Protocol, Correction, Editorial, General Commentary, Hypothesis and Theory, Mini Review, Opinion, Original Research, Perspective, Review and Systematic Review.
All manuscripts must be submitted directly to the section Cardiovascular Biologics and Regenerative Medicine, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Cardiovascular Biologics and Regenerative Medicine will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Cardiovascular Medicine.